Activation of α1B-adrenoceptors contributes to intermittent hypobaric hypoxia-improved postischemic myocardial performance via inhibiting MMP-2 activation

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 306, Issue 11, 2014, Pages

  Gao, Ling ^a   Chen, Le ^a   Lu, Zhi Zhen ^b   Gao, Hong ^a   Wu, Lan ^a   Chen, Yi Xiong ^a   Zhang, Cai Mei ^a   Jiang, Yu Kun ^a   Jing, Qing ^a   Zhang, You Yi ^b   Yang, Huang Tian ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Peking University Health Science Center   (China)

Author keywords

Intermittent hypobaric hypoxia; Ischemia reperfusion injury; Matrix metalloenzymes 2; Mitochondria; 1 adrenoceptors

Indexed keywords

3 NITROTYROSINE; ALPHA 1A ADRENERGIC RECEPTOR; ALPHA 1B ADRENERGIC RECEPTOR; ALPHA 1D ADRENERGIC RECEPTOR; ALPHA ACTININ; CYTOCHROME C; DOXYCYCLINE; GELATINASE A; LACTATE DEHYDROGENASE; PEROXYNITRITE; PRAZOSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 4; TROPONIN I;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; HEART INFARCTION SIZE; HEART MUSCLE CONTRACTILITY; HEART PERFORMANCE; HEART PERFUSION; HEART PROTECTION; HYPOBARISM; INTERMITTENT HYPOBARIC HYPOXIA; INTERMITTENT HYPOXIA; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY;

INTERMITTENT HYPOBARIC HYPOXIA; ISCHEMIA-REPERFUSION INJURY; MATRIX METALLOENZYMES-2; MITOCHONDRIA; Α1-ADRENOCEPTORS;

ACTININ; ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; ANIMALS; ANOXIA; DOXYCYCLINE; MALE; MATRIX METALLOPROTEINASE 2; MYOCARDIAL ISCHEMIA; MYOCARDIUM; PRAZOSIN; PROTEIN KINASE C-EPSILON; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, ALPHA-1; REPERFUSION INJURY; SIGNAL TRANSDUCTION; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 84901699418     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00772.2013     Document Type: Article

References (69)

1. Ali MA, Cho WJ, Hudson B, Kassiri Z, Granzier H, Schulz R. Titin is a target of matrix metalloproteinase-2: implications in myocardial ischemia/ reperfusion injury. Circulation 122: 2039-2047, 2010.
2. Ali MA, Stepanko A, Fan X, Holt A, Schulz R. Calpain inhibitors exhibit matrix metalloproteinase-2 inhibitory activity. Biochem Biophys Res Commun 423: 1-5, 2012.
3. Asemu G, Papousek F, Ostadal B, Kolar F. Adaptation to high altitude hypoxia protects the rat heart against ischemia-induced arrhythmias. Involvement of mitochondrial K(ATP) channel. J Mol Cell Cardiol 31: 1821-1831, 1999.
4. Aydemir-Koksoy A, Bilginoglu A, Sariahmetoglu M, Schulz R, Turan B. Antioxidant treatment protects diabetic rats from cardiac dysfunction by preserving contractile protein targets of oxidative stress. J Nutr Biochem 21: 827-833, 2010.
5. Banerjee A, Locke-Winter C, Rogers KB, Mitchell MB, Brew EC, Cairns CB, Bensard DD, Harken AH. Preconditioning against myocardial dysfunction after ischemia and reperfusion by an alpha 1-adrenergic mechanism. Circ Res 73: 656-670, 1993.
6. Bellosta S, Gomaraschi M, Canavesi M, Rossoni G, Monetti M, Franceschini G, Calabresi L. Inhibition of MMP-2 activation and release as a novel mechanism for HDL-induced cardioprotection. FEBS Lett 580: 5974-5978, 2006.
7. Camara AK, Bienengraeber M, Stowe DF. Mitochondrial approaches to protect against cardiac ischemia and reperfusion injury. Front Physiol 2: 13, 2011.
8. Chan CY, Chen YS, Lee HH, Huang HS, Lai YL, Chen CF, Ma MC. Erythropoietin protects postischemic hearts by preventing extracellular matrix degradation: role of Jak2-ERK pathway. Life Sci 81: 717-723, 2007.
9. 2+ exchange mechanisms. Am J Physiol Cell Physiol 290: C1221-C1229, 2006.
10. Cheung PY, Sawicki G, Wozniak M, Wang W, Radomski MW, Schulz R. Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation 101: 1833-1839, 2000.
11. Chow AK, Cena J, El-Yazbi AF, Crawford BD, Holt A, Cho WJ, Daniel EE, Schulz R. Caveolin-1 inhibits matrix metalloproteinase-2 activity in the heart. J Mol Cell Cardiol 42: 896-901, 2007.
12. Coker ML, Doscher MA, Thomas CV, Galis ZS, Spinale FG. Matrix metalloproteinase synthesis and expression in isolated LV myocyte preparations. Am J Physiol Heart Circ Physiol 277: H777-H787, 1999.
13. D'Annunzio V, Donato M, Erni L, Miksztowicz V, Buchholz B, Carrion CL, Schreier L, Wikinski R, Gelpi RJ, Berg G, Basso N. Rosuvastatin given during reperfusion decreases infarct size and inhibits matrix metalloproteinase-2 activity in normocholesterolemic and hypercholesterolemic rabbits. J Cardiovasc Pharmacol 53: 137-144, 2009.
14. Del PV, Garcia-Godos F, Woolcott OO, Marticorena JM, Rodriguez V, Gutierrez I, Fernandez-Davila L, Contreras A, Valdivia L, Robles J, Marticorena EA. Improvement of myocardial perfusion in coronary patients after intermittent hypobaric hypoxia. J Nucl Cardiol 13: 69-74, 2006.
15. Donato M, D'Annunzio V, Buchholz B, Miksztowicz V, Carrion CL, Valdez LB, Zaobornyj T, Schreier L, Wikinski R, Boveris A, Berg G, Gelpi RJ. Role of matrix metalloproteinase-2 in the cardioprotective effect of ischaemic postconditioning. Exp Physiol 95: 274-281, 2010.
16. Donnini S, Monti M, Roncone R, Morbidelli L, Rocchigiani M, Oliviero S, Casella L, Giachetti A, Schulz R, Ziche M. Peroxynitrite inactivates human-tissue inhibitor of metalloproteinase-4. FEBS Lett 582: 1135-1140, 2008.
17. Fert-Bober J, Leon H, Sawicka J, Basran RS, Devon RM, Schulz R, Sawicki G. Inhibiting matrix metalloproteinase-2 reduces protein release into coronary effluent from isolated rat hearts during ischemia-reperfusion. Basic Res Cardiol 103: 431-443, 2008.
18. 2+ overload in cardiomyocytes. Cardiovasc Res 75: 584-595, 2007.
19. Gao XM, Wang BH, Woodcock E, Du XJ. Expression of active alpha(1B)-adrenergic receptors in the heart does not alleviate ischemic reperfusion injury. J Mol Cell Cardiol 32: 1679-1686, 2000.
20. Giricz Z, Lalu MM, Csonka C, Bencsik P, Schulz R, Ferdinandy P. Hyperlipidemia attenuates the infarct size-limiting effect of ischemic preconditioning: role of matrix metalloproteinase-2 inhibition. J Pharmacol Exp Ther 316: 154-161, 2006.
21. Gross G, Hanft G, Rugevics C. 5-Methyl-urapidil discriminates between subtypes of the alpha 1-adrenoceptor. Eur J Pharmacol 151: 333-335, 1988.
22. Hanft G, Gross G. Subclassification of alpha 1-adrenoceptor recognition sites by urapidil derivatives and other selective antagonists. Br J Pharmacol 97: 691-700, 1989.
23. Hassouna A, Matata BM, Galinanes M. PKC-epsilon is upstream and PKC-alpha is downstream of mitoKATP channels in the signal transduction pathway of ischemic preconditioning of human myocardium. Am J Physiol Cell Physiol 287: C1418-C1425, 2004.
24. Heusch G, Boengler K, Schulz R. Cardioprotection: nitric oxide, protein kinases, mitochondria. Circulation 118: 1915-1919, 2008.
25. Hu K, Nattel S. Mechanisms of ischemic preconditioning in rat hearts. Involvement of alpha 1B-adrenoceptors, pertussis toxin-sensitive G proteins, and protein kinase C. Circulation 92: 2259-2265, 1995.
26. Hughes BG, Fan X, Cho WJ, Schulz R. MMP-2 is localized to the mitochondria-associated membrane of the heart. Am J Physiol Heart Circ Physiol 306: H764-H770, 2014.
27. Hurtado A. Some clinical aspects of life at high altitudes. Ann Intern Med 53: 247-258, 1960.
28. Johnson JA, Gray MO, Chen CH, Mochly-Rosen D. A protein kinase C translocation inhibitor as an isozyme-selective antagonist of cardiac function. J Biol Chem 271: 24962-24966, 1996.
29. Kandasamy AD, Chow AK, Ali MA, Schulz R. Matrix metalloproteinase-2 and myocardial oxidative stress injury: beyond the matrix. Cardiovasc Res 85: 413-423, 2010.
30. Kopecky M, Daum S. Adaptation of the myocardium to altitude anoxia. Cesk Fysiol 7: 218-219, 1958.
31. Lalu MM, Csonka C, Giricz Z, Csont T, Schulz R, Ferdinandy P. Preconditioning decreases ischemia/reperfusion-induced release and activation of matrix metalloproteinase-2. Biochem Biophys Res Commun 296: 937-941, 2002.
32. Li SJ, Wu YN, Kang Y, Yin YQ, Gao WZ, Liu YX, Lou JS. Noninvasive limb ischemic preconditioning protects against myocardial I/R injury in rats. J Surg Res 164: 162-168, 2010.
33. Mayers I, Hurst T, Puttagunta L, Radomski A, Mycyk T, Sawicki G, Johnson D, Radomski MW. Cardiac surgery increases the activity of matrix metalloproteinases and nitric oxide synthase in human hearts. J Thorac Cardiovasc Surg 122: 746-752, 2001.
34. Meerson FZ, Gomzakov OA, Shimkovich MV. Adaptation to high altitude hypoxia as a factor preventing development of myocardial ischemic necrosis. Am J Cardiol 31: 30-34, 1973.
35. Meerson FZ, Kopylov I, Baldenkov GN. Increase of alpha 1-adrenoreactivity of the rat heart in adaptation to periodic hypoxia. Biull Eksp Biol Med 111: 570-572, 1991.
36. Muller AL, Hryshko LV, Dhalla NS. Extracellular and intracellular proteases in cardiac dysfunction due to ischemia-reperfusion injury. Int J Cardiol 164: 39-47, 2013.
37. Naderi R, Imani A, Faghihi M. Phenylephrine produces late pharmacological preconditioning in the isolated rat heart. Eur J Pharmacol 627: 203-208, 2010.
38. Neckar J, Szarszoi O, Koten L, Papousek F, Ost'Adal B, Grover GJ, Kolar F. Effects of mitochondrial K(ATP) modulators on cardioprotection induced by chronic high altitude hypoxia in rats. Cardiovasc Res 55: 567-575, 2002.
39. Przyklenk K, Whittaker P. Cardioprotection via adaptation to hypoxia: expanding the timeline and targets? Basic Res Cardiol 106: 325-328, 2011.
40. Rehring TF, Friese RS, Cleveland JC, Meng X, Robertson FG, Harken AH, Bannerjee A. Alpha-adrenergic preservation of myocardial pH during ischemia is PKC isoform dependent. J Surg Res 63: 324-327, 1996.
41. Riches K, Morley ME, Turner NA, O'Regan DJ, Ball SG, Peers C, Porter KE. Chronic hypoxia inhibits MMP-2 activation and cellular invasion in human cardiac myofibroblasts. J Mol Cell Cardiol 47: 391-399, 2009.
42. Rongen GA, Smits P, Thien T. Role of norepinephrine in ischemic preconditioning in rabbit myocardium. Circulation 89: 2460-2461, 1994.
43. Rorabaugh BR, Ross SA, Gaivin RJ, Papay RS, McCune DF, Simpson PC, Perez DM. alpha1A-but not alpha1B-adrenergic receptors precon-dition the ischemic heart by a staurosporine-sensitive, chelerythrineinsensitive mechanism. Cardiovasc Res 65: 436-445, 2005.
44. Schulze CJ, Wang W, Suarez-Pinzon WL, Sawicka J, Sawicki G, Schulz R. Imbalance between tissue inhibitor of metalloproteinase-4 and matrix metalloproteinases during acute myocardial ischemia-reperfusion injury. Circulation 107: 2487-2492, 2003.
45. Spanikova A, Ivanova M, Matejikova J, Ravingerova T, Barancik M. Influence of ischemia/reperfusion and modulation of PI3K/Akt kinase pathway on matrix metalloproteinase-2 in rat hearts. Gen Physiol Biophys 29: 31-40, 2010.
46. Strniskova M, Ravingerova T, Neckar J, Kolar F, Pastorekova S, Barancik M. Changes in the expression and/or activation of regulatory proteins in rat hearts adapted to chronic hypoxia. Gen Physiol Biophys 25: 25-41, 2006.
47. Sung MM, Schulz CG, Wang W, Sawicki G, Bautista-Lopez NL, Schulz R. Matrix metalloproteinase-2 degrades the cytoskeletal protein alpha-actinin in peroxynitrite mediated myocardial injury. J Mol Cell Cardiol 43: 429-436, 2007.
48. Szabo C, Ischiropoulos H, Radi R. Peroxynitrite: biochemistry, pathophysiology and development of therapeutics. Nat Rev Drug Discov 6: 662-680, 2007.
49. Taliyan R, Singh M, Sharma PL, Yadav HN, Sidhu KS. Possible involvement of alpha1-adrenergic receptor and K(ATP) channels in cardioprotective effect of remote aortic preconditioning in isolated rat heart. J Cardiovasc Dis Res 1: 145-151, 2010.
50. Tao L, Gao E, Jiao X, Yuan Y, Li S, Christopher TA, Lopez BL, Koch W, Chan L, Goldstein BJ, Ma XL. Adiponectin cardioprotection after myocardial ischemia/reperfusion involves the reduction of oxidative/nitrative stress. Circulation 115: 1408-1416, 2007.
51. Tsang S, Wu S, Liu J, Wong TM. Testosterone protects rat hearts against ischaemic insults by enhancing the effects of alpha(1)-adrenoceptor stimulation. Br J Pharmacol 153: 693-709, 2008.
52. Tsuchida A, Liu Y, Liu GS, Cohen MV, Downey JM. Alpha 1-adrenergic agonists precondition rabbit ischemic myocardium independent of adenosine by direct activation of protein kinase C. Circ Res 75: 576-585, 1994.
53. Wang W, Sawicki G, Schulz R. Peroxynitrite-induced myocardial injury is mediated through matrix metalloproteinase-2. Cardiovasc Res 53: 165-174, 2002.
54. Wang W, Schulze CJ, Suarez-Pinzon WL, Dyck JR, Sawicki G, Schulz R. Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation 106: 1543-1549, 2002.
55. 2+ overload injury via protein kinase C signaling pathway. J Mol Cell Cardiol 30: 2423-2435, 1998.
56. Wang YP, Cui F, Zhang LP, Yang CY, Guan Y, Zhou ZN, Zhang Y. Effect of chronic intermittent hypobaric hypoxia on alpha(1)-adrenergic receptor of myocardium participates in the cardioprotection. Sheng Li Xue Bao 61: 21-26, 2009.
57. Wang ZH, Cai XL, Wu L, Yu Z, Liu JL, Zhou ZN, Liu J, Yang HT. Mitochondrial energy metabolism plays a critical role in the cardioprotection afforded by intermittent hypobaric hypoxia. Exp Physiol 97: 1105-1118, 2012.
58. Wang ZH, Chen YX, Zhang CM, Wu L, Yu Z, Cai XL, Guan Y, Zhou ZN, Yang HT. Intermittent hypobaric hypoxia improves postischemic recovery of myocardial contractile function via redox signaling during early reperfusion. Am J Physiol Heart Circ Physiol 301: H1695-H1705, 2011.
59. 2+ overload injury. Life Sci 76: 559-572, 2004.
60. Xie Y, Zhu Y, Zhu WZ, Chen L, Zhou ZN, Yuan WJ, Yang HT. Role of dual-site phospholamban phosphorylation in intermittent hypoxia-induced cardioprotection against ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 288: H2594-H2602, 2005.
61. Xu WQ, Yu Z, Xie Y, Huang GQ, Shu XH, Zhu Y, Zhou ZN, Yang HT. Therapeutic effect of intermittent hypobaric hypoxia on myocardial infarction in rats. Basic Res Cardiol 106: 329-342, 2011.
62. Yang H, Zhang Y, Wang ZH, Zhou ZN. Protective effects of chronic intermittent hypoxia against myocardial ischemia reperfusion injury. In: Intermittent Hypoxia and Human Diseases, edited by Lei X, Serebrovskaya TV. New York: Springer, 2012.
63. Yang HT, Endoh M. Dissociation of the positive inotropic effect of methoxamine from the hydrolysis of phosphoinositide in rabbit ventricular myocardium: a comparison with the effects of phenylephrine and the subtype of the alpha-1 adrenoceptor involved. J Pharmacol Exp Ther 269: 732-742, 1994.
64. Yang X, Cohen MV, Downey JM. Mechanism of cardioprotection by early ischemic preconditioning. Cardiovasc Drugs Ther 24: 225-234, 2010.
65. Yu GS, Han C. Role of alpha 1A-and alpha 1B-adrenoceptors in phenylephrine-induced positive inotropic response in isolated rat left atrium. J Cardiovasc Pharmacol 24: 745-752, 1994.
66. 2+ homeostasis and preventing calpain activation. Circ J 76: 1993-2002, 2012.
67. Zhang YY, Xu KM, Han C. Alpha(1)-adrenoceptor subtypes mediating inotropic responses in rat heart. J Pharmacol Exp Ther 291: 829-836, 1999.
68. Zhu WZ, Xie Y, Chen L, Yang HT, Zhou ZN. Intermittent high altitude hypoxia inhibits opening of mitochondrial permeability transition pores against reperfusion injury. J Mol Cell Cardiol 40: 96-106, 2006.
69. Zhuang J, Zhou Z. Protective effects of intermittent hypoxic adaptation on myocardium and its mechanisms. Biol Signals Recept 8: 316-322, 1999.